Clinical Trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-11-07; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Recruiting 2023-12-06
Trial Details
NCT Number NCT06128551
Lead Sponsor Revolution Medicines, Inc.
Conditions Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Enrollment 534 participants
Start Date 2023-11-14
Primary Completion 2028-12 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-03